Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

global access

- PMLiVE

NICE rejects Akcea’s rare inherited disorder drug Waylivra

Draft guidance deems drug too costly for NHS use

- PMLiVE

GSK divests travel vaccines to Bavarian Nordic as part of strategic refocus

Agreed divestment deal is worth up to €955m

- PMLiVE

GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

Pricing pressures increase amid intense political scrutiny

- PMLiVE

Antibiotic biotech Melinta files for bankruptcy

Worries over antibiotic business model continue to mount

- PMLiVE

NICE knocks back Roche’s Tecentriq for small cell lung cancer

Insufficient evidence to approve use in SCLC on the NHS

- PMLiVE

Astellas bulks up immuno-oncology pipeline with $665m Xyphos deal

Closely follows $3bn acquistion of gene therapy specialist Audentes

- PMLiVE

Boehringer Ingelheim to manufacture first biologic in China under new reforms

German pharma will manufacture BeiGene's PD-1 inhibitor

- PMLiVE

New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals

The latest movers in pharma

- PMLiVE

AZ, Merck win FDA approval for Lynparza in pancreatic cancer

New treatment option for subset of patients with BRCA-mutations

- PMLiVE

Google’s DeepMind AI outperforms doctors on breast cancer screening

System reduced false positive and false negative decisions

- PMLiVE

How AI is transforming the way we collect market insights

Leveraging new technologies to gather actionable insights

- PMLiVE

Saving Time

Of all the challenges facing humanity, one thing continues to dominate: the pursuit of saving time.

Page & Page Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links